Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury.
Company Profile
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparations (325412)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
T: 650-543-5470
ir@unicycive.com
Company Contact
Unicycive Therapeutics, Inc.
1975 W El Camino Real
Ste 204
Mountain View, CA 94040
T: 650-351-4495
info@unicycive.com